Core Insights - The company reported a revenue of 701 million yuan and a net profit attributable to shareholders of 57.27 million yuan for Q3 2025, facing performance pressure due to external environment complexities and market demand fluctuations [1] - Despite challenges, the company is not slowing down its development pace and is focusing on strengthening its operational foundation for future growth [1] Academic Marketing and Product Value - The company is enhancing its academic marketing system by focusing on evidence-based research, updating academic materials, and promoting products into authoritative guidelines [2] - A total of 248 sets of academic materials have been updated, covering key product lines such as respiratory and cardiovascular diseases, which align clinical value with market needs [2] - The company has successfully integrated 10 core products into 6 authoritative guidelines, which is expected to boost prescription willingness among doctors and drive sales growth [2] Diversified Sales Channels - To mitigate risks from single-channel dependency, the company is actively developing a multi-faceted sales strategy, including agency recruitment, OTC, channel sales, and clinic distribution [3] - The company is enhancing the quality and academic promotion capabilities of its agents through standardized admission criteria and professional training [3] - In the OTC sector, the company is focusing on core products and collaborating with new retail channels to stabilize market prices while achieving success in expanding into small chain and generic drug markets [3] Operational Improvements and Future Outlook - The company is strengthening evidence-based medical support and building an academic marketing team to enhance professional and academic capabilities [4] - Despite facing performance pressure, the company is implementing precise measures to solidify its operational foundation, showing signs of marginal improvement in its fundamentals [4] - With the continued expansion of terminal coverage for core products and the gradual release of academic promotion effects, the company is expected to gradually reverse the performance volatility and achieve more stable growth [4]

2025年2月20日， 希毅医学联合思宇MedTech，在深圳先进技术研究院举办了 "ReDe for 2025：医疗器械海外增长新范式"研讨会 。 分享一：中国高值耗材出海之路 分享嘉宾：元心科技海外负责人 黄俊明 在全球化浪潮的推动下，中国医疗器械企业正迎来前所未有的海外发展机遇。然而，如何突破海外市场壁垒、实现业务模式的转型升级，是每一个企业亟待解决的 问题。本次研讨会聚焦于此，旨在为中国医疗器械企业开辟海外增长的新路径。 一、出海策略：市场分析与营销实践 1. 市场分析：理论容量与实际容量 市场分析需结合理论容量（如病患数量）和实际容量（如医生数量、手术量等）。实际容量受医疗条件和医生数量限制，因此不能仅看病患数量。例如，神经外科 高值耗材的实际容量取决于神经外科医生的数量，而非病患数量。不同国家和地区市场差异大：欧美市场虽大但进入门槛高，东南亚和拉美市场虽小但潜力大。 2. 竞争分析：差异化与市场定位 竞争分析需关注竞争对手的市场份额、推广策略和合作伙伴。企业需通过差异化的产品力和品牌力提升竞争力，而非仅靠低价竞争。价格策略应由市场竞争决定， 而非单纯由国家贫富决定，竞争越激烈，价格越低。 3. 学 ...